Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive

Ramón C Hermida1, Carlos Calvo, Diana E Ayala

  • 1Bioengineering Laboratory, University of Vigo, Campus Universitario, Vigo, Spain. rhermida@tsc.uvigo.es

Hypertension (Dallas, Tex. : 1979)
|September 8, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Critical Review of the Methodological Shortcoming of Ambulatory Blood Pressure Monitoring and Cognitive Function Studies.

Clocks & sleep·2025
Same author

Findings and Methodological Shortcomings of Investigations Concerning the Relationship Between Sleep Duration and Blood Pressure: A Comprehensive Narrative Review.

Journal of cardiovascular development and disease·2025
Same author

Impact of Daytime and Nighttime Blood Pressure and Nocturnal Blood Pressure Fall on Heart Failure Risk in Treated Hypertension.

American journal of hypertension·2025
Same author

Circadian chronotherapies of coronary heart disease and its biological risk factors: A United States Prescribers' Digital Reference-based review.

Chronobiology international·2024
Same author

Response to Comment on: Risk of heart failure in ambulatory resistant hypertension: a meta-analysis of observational studies.

Hypertension research : official journal of the Japanese Society of Hypertension·2024
Same author

Risk of heart failure in ambulatory resistant hypertension: a meta-analysis of observational studies.

Hypertension research : official journal of the Japanese Society of Hypertension·2024

Administering valsartan at bedtime, not upon waking, significantly improves the blood pressure diurnal/nocturnal ratio. This timing adjustment in hypertension treatment also reduces microalbuminuria and associated cardiovascular risk.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Previous research suggests bedtime valsartan enhances the diurnal/nocturnal blood pressure ratio without compromising efficacy.
  • Essential hypertension management often involves optimizing circadian blood pressure patterns to mitigate cardiovascular and renal risks.

Purpose of the Study:

  • To investigate whether improving the diurnal/nocturnal blood pressure ratio through bedtime valsartan administration can reduce microalbuminuria in hypertensive patients.
  • To evaluate the impact of valsartan timing on circadian blood pressure patterns and urinary albumin excretion.

Main Methods:

  • A prospective, randomized, open-label trial involving 200 nonproteinuric patients with essential hypertension.
  • Patients received valsartan (160 mg/d) either at bedtime or upon awakening for 3 months.

Related Experiment Videos

  • Ambulatory blood pressure monitoring and wrist actigraphy were used to assess blood pressure and physical activity, calculating diurnal and nocturnal means.

    • Main Results:

    • Both treatment times achieved similar overall blood pressure reduction.
    • Bedtime valsartan significantly increased the diurnal/nocturnal blood pressure ratio (from 7.5 to 12.2), while morning administration did not.
    • Urinary albumin excretion decreased by 41% with bedtime valsartan, correlated with increased diurnal/nocturnal ratio and reduced nocturnal blood pressure.

    Conclusions:

    • Bedtime administration of valsartan normalizes the circadian blood pressure pattern, promoting a 'dipper' profile.
    • This normalization is linked to reduced microalbuminuria and plasma fibrinogen, potentially lowering cardiovascular risk in non-dipper hypertensive individuals.
    • Optimizing antihypertensive medication timing offers a strategy to improve cardiovascular and renal outcomes in hypertension.